Abstract:
Disclosed are pyrazolyl derivative compounds or purified stereoisomers or stereoisomer mixtures of said compounds and their salts or prodrug forms thereof which have structural formula (I) or (II): wherein the variables R, R1, R2, R5 and R6 are as defined in the specification. The compounds are useful for the treatment or prevention of diseases and/or behaviors involving the 5-HT2C receptor.
Abstract translation:公开了具有结构式(I)或(II)的所述化合物及其盐或前药形式的吡唑基衍生物化合物或纯化的立体异构体或立体异构体混合物:其中变量R 1,R 1, SUB 2,R 5和R 6如说明书中所定义。 该化合物可用于治疗或预防涉及5-HT 2C受体的疾病和/或行为。
Abstract:
A technique is provided for the alignment of an H/D puller for use in a cyclotron. One aspect of the technique comprises magnetically attaching a pair of feeler gages to an alignment tool for use in aligning the H/D puller. The magnetic retention of the feeler gages allows a field engineer to make the desired adjustments to align the H/D puller. Another aspect of the present technique provides for the H/D puller to include a replaceable tip such that the tip may be replaced without removing the H/D puller. Because the H/D puller is not removed and replaced, the alignment of the H/D puller to the ion source is maintained.
Abstract:
To obviate inefficient use of bandwidth in a packetised system, such as a broadband ATM domain, the use or amount of header information sent in relation to a channel is restricted by one of two principal mechanisms, as exemplified in FIGS. 3 and 4. First, control information incident to a packet interface (20) is interrogated by a processor (21) to determine (50) packet length requirements. A packet length indicator is then generated (52) for inclusion within a header (44) of a packet. Alternatively, a frame (30) is pre-partitioned (60) into several packets (32-42) having different lengths. An addressed subscriber unit (28) is allocated (64) a particular channel, i.e. at least one particular packet within the frame (30), based on data throughput requirements (62), whereby the location of the packet within the frame inherently identifies the length of the packet. Optionally, the data rate used within that packet may also be identified inherently by the location of the packet within the frame (30).
Abstract:
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
Abstract:
A method for multiple context analysis of software applications in a multiprocessing (22, 23), multithreaded computer environment utilizes instrumentation code inserted (54, 55) into the applications. For each execution (67) of the application (60), a context set is selected (62). Execution of the instrumented code (67) provides information for analysis in an instrumentation buffer (82) addressed by a reserved register (80) or buffer pointer. The operating system is responsible for providing in the reserved register (80) the address of the instrumentation buffer (82) appropriate for each instrumented context executed. When the application (60) is done with an instrumentation buffer (82), the buffer may be processed by filter software (68). The combination of using a reserved register (80) and allowing the operating system to keep track of relevant context switches allows applications to be instrumented (54, 55) for various context sets without the necessity of modifying (53) or recompiling (52) the application software (60).
Abstract:
An antibacklash beveled gear drive is disclosed. The drive is constructed adjust for intial misalignment and subsequent wear. One of the gears is journaled on a driven shaft and has a biasing means which bump the gears into engagement.
Abstract:
This disclosure is directed to pulsed spectropolarimeters for conducting remote, non-perturbative measurements of the local magnetic field, density and temperature fields of a magnetized plasma medium. In one aspect, a pulsed spectropolarimeter includes a light source emitting a polarized light pulse having sufficiently narrow spatial extent at a prescribed wavelength and a light gathering optical system including a light gathering optic having an optic axis directed toward the medium and positioned to collect and collimate a predetermined solid angle of the scattered emission by the pulse in the backward direction, toward the source, while preserving the polarization state of the emission. A proportion of the emission is redirected to a spectrometer detector to determine the spectral distribution of the emission. A second optical collection and spectrometer system collects emission other than backscatter localized to the intersection of the pulse trajectory and the focus of this collection system.
Abstract:
A modular solution mining method may include the steps of: providing an injection wellbore, the injection wellbore including a horizontal injection portion, in which the horizontal injection portion includes a toe end and heel end; providing a production wellbore, in which the production wellbore includes a horizontal production portion that is proximate to the toe end; injecting a solvent into the horizontal injection portion; generating a turbulent solvent flow proximate to the toe end to generate a mineral solution and an initial cavern proximate to the horizontal production portion; and motivating the mineral solution from the initial cavern, into the horizontal production portion, and to a surface location. Optionally, the method may include the step of repositioning the turbulent solvent flow to be closer to heel ends to generate mineral solution and subsequent caverns further from horizontal production wellbore.
Abstract:
Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A=pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g., cytotoxic therapies.